von Willebrand Disease

New Data Further Demonstrate Efficacy of Humate-P

Published in Women's Health Weekly, August 3rd, 2000

Results from studies provide additional evidence that treatment with Humate-P (Antihemophilic Factor/von Willebrand Factor Complex [Human] Dried, Pasteurized) results in "excellent/good" efficacy for treating bleeding events caused by von Willebrand Disease (vWD) and is associated with an excellent safety profile.

The data were presented at the World Federation of Hemophilia's Annual Meeting, "Hemophilia 2000 Congress," held in King of Prussia, Pennsylvania, during July 2000. Humate-P is the only factor concentrate approved in the United States for the treatment of vWD, the most common inherited bleeding disorder estimated to effect more than 2.5 million people in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-08-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry